* PHARMAXON *
2004 - Méditerranée
Marseille
www.pharmaxon.com Discovery, Drugs
(also, Contract, Research)
Key words: Cell mobility, CNS
Mission: to develop new treatments or new research services to third parties, specialized in controlling cell mobility, as a technological breakthrough in neurology and neuro-oncology
Clients: Prescribers, Pharmaceutical industry, Research labs
contact@pharmaxon.com
Age: 7 year(s)
Identity| TYPE/MANAGEMENT/INVESTORS | FINANCES/STATUS |
|---|
| Spin-off |
Norreel (Jean-Chrétien) [co-founder, born 1970, Ph.D. neurosciences]
Sc.Dir.-CSO: Rougon (Geneviève) [co-founder, Ph.D., ex-CNRS, IBDM]
Oper.Dir.-COO:
Fin.Dir.-CFO:
BusDev:
Financers (Hist.): Inserm-Transfert Initiative, Esperante, Primavéris, CAAP Création, SHAM
Communication: no website news update since 2009, no legal information available since end 2009 | Turnover (M€) : 0.062 (2009), 0.031 (2007), 0.13 (2006)
Total funding (M€) : 2.2
Last funding (M€) : 1.7
Focus : CNS
Position : Preclin
Company confirm : none |
History | DATE | MILESTONE | TYPE | TIME |
|---|
| 2009 .11 | 1st round-financing : € 1.7 Million by SHAM (Société Hospitalière d'Assurances Mutuelles) and Primavéris | RFINA | [5 years] |
| 2008 .11 | Nomination : Glenn Stanley, as CEO, replacing Pascal Deschaseaux, moving as Gelarc Managing Director in Lyon (France) | ORGN | [4 years] |
| 2007 .05 | Licensing-in of PSA mimetic peptides from CNRS, 2 Universities and Schaffer-N (Denmark) | LICIN | [2 years] |
| 2006 .10 | Seed financing : 0.5 M€, by Inserm-Transfert Initiative, Esperante, Primavéris, Crédit Agricole AP Création | SFIN | [2 years] |
| 2004 .09 | Company founded by Pascal Deschaseaux [born 1960, M.D., MBA, ex-Pierre Fabre, Johnson & Johnson, Merck KGaA], Geneviève Rougon, Jean-Chrétien Norreel, as a spin-off from IBDM (Institut de Biologie et du Développement de Marseille-Luminy) | ORGF | [0 year] | Actualisation / Updating: 28-Sep-2011 |
|
